Imvax, Inc., a Philadelphia, PA-based clinical-stage biotechnology company, raised $112m in Series C financing.
The round was led by existing investor HP WILD Holding AG, with participation from other major shareholders – Ziff Capital Partners, Magnetar Capital, and TLP Investment Partners and new institutional investor Invus.
The company intends to use the funds to continue clinical development of lead product candidate IGV-001 for treatment of GBM through Phase 2, broaden the development portfolio into additional oncology therapeutic indications and expand its corporate and manufacturing capabilities.
Led by Peter B. Corr, Ph.D., Co-Founder and Chairman of the Board, and John Furey, CEO, Imvax is a clinical-stage biotechnology company committed to improving immunotherapy for patients with intractable solid tumor cancers. The company’s lead product, IGV-001, which is being studied in patients with newly diagnosed GBM, is a neo-antigen immunotherapy platform that engages both the innate and adaptive elements of the immune system. Other studies have also supported preclinical proof of concept in multiple solid tumors beyond GBM, such as pancreatic, breast and hepatocellular carcinoma.